Company Description
Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps).
It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics.
The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications.
It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients.
The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015.
Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah.
On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7.
It had filed for Chapter 11 bankruptcy on November 9, 2023.
| Country | UT |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Bradley C. Robinson |
Contact Details
Address: 615 Arapeen Drive, Suite 300 Salt Lake City, Utah 84108 United States | |
| Phone | 888-407-9761 |
| Website | predtechgroup.com |
Stock Details
| Ticker Symbol | PRED |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001382943 |
| CUSIP Number | 74039H102 |
| ISIN Number | US74039H1023 |
| Employer ID | 90-1139372 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley C. Robinson | Chief Executive Officer, President and Director |
| Dr. Michael Dey Ph.D. | Chief Executive Officer of Predictive Therapeutics and Director |
| Dr. Bruce D. Forrest B.S., M.B.A., M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2022 | 15-12G | Securities registration termination |
| Feb 4, 2022 | 8-K | Current Report |
| Jan 24, 2022 | 8-K | Current Report |
| Jan 6, 2022 | 8-K | Current Report |
| Oct 7, 2021 | 8-K | Current Report |
| Sep 28, 2021 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Aug 11, 2021 | 8-K | Current Report |
| Jun 21, 2021 | 8-K | Current Report |
| May 17, 2021 | 10-Q | Quarterly Report |
| Mar 10, 2021 | 8-K | Current Report |